Resistance pattern of ciprofloxacin against different pathogens

Oman Medical Journal

Volumn 25, Issue 4, 2010, Pages 294-298

  Ali, Syeda Q ^a   Zehra, Ale ^a   Naqvi, Baquar S ^a   Shah, Shahjahan ^a   Bushra, Rabia ^b  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b ZIAUDDIN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CIPROFLOXACIN RESISTANCE; DISK DIFFUSION; ESCHERICHIA COLI; INFECTIOUS AGENT; KLEBSIELLA PNEUMONIAE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA SEROVAR TYPHI; STAPHYLOCOCCUS AUREUS; ZONE OF INHIBITION;

EID: 84861855653     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: 10.5001/omj.2010.85     Document Type: Article

References (48)

1. Denys GA, Koch KM, Dowzicky MJ. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Am J Infect Control 2007 Oct;35(8):521-526.
2. Johnson AP, Pearson A, Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. J Antimicrob Chemother 2005 Sep;56(3):455-462.
3. Sharma R, Sharma CL, Kapoor B. Antibacterial resistance: current problems and possible solutions. Indian J Med Sci 2005 Mar;59(3):120-129.
4. Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ. Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health 2006;2:6.
5. Felmingham D, Cantón R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007 Aug;55(2):111-118.
6. Sharma R, Sharma CL, Kapoor B. Antibacterial resistance: current problems and possible solutions. Indian J Med Sci 2005 Mar;59(3):120-129.
7. Bonev B, Hooper J, Parisot J. Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method. J Antimicrob Chemother 2008 Jun;61(6):1295-1301.
8. Jang CH, Park SY. Emergence of ciprofloxacin-resistant pseudomonas in pediatric otitis media. Int J Pediatr Otorhinolaryngol 2003 Apr;67(4):313-316.
9. Mushtaq MA. What after ciprofloxacin and ceftriaxone in treatment of Salmonella Typhi. Pak J Med Sci 2006;22:51-54.
10. Nweneka CV, Tapha-Sosseh N, Sosa A. Curbing the menace of antimicrobial resistance in developing countries. Harm Reduct J 2009;6:31.
11. Campoli-Richards DM, Monk JP, Price A, Benflied P, Todd PA, Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetics properties and therapeutics use. Drugs 1998;35:373-447.
12. Eliopoulos GM. In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs 1995;49(Suppl 2):48-57.
13. Bazile-Pham-Khac S, Truong QC, Lafont JP, Gutmann L, Zhou XY, Osman M, et al. Resistance to fluoroquinolones in Escherichia coli isolated from poultry. Antimicrob Agents Chemother 1996 Jun;40(6):1504-1507.
14. Lontie ML, Vanerdeweghe PE. Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago).
15. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003 May;47(5):1681-1688.
16. Chambers HF. Sulfonamides, Trimethoprim, & Quinolones. In Katzung BG. Basic & Clinical Pharmacology, Boston, 2004. p.777-780.
17. Brown JC, Shanahan PM, Jesudason MV, Thomson CJ, Amyes SG. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J Antimicrob Chemother 1996 May;37(5):891-900. P
18. Threlfall EJ, Skinner JA, Ward LR. Decreased in vitro susceptibility to ciprofloxacin in resistant Salmonella serotypes typhi and paratyphi A. J Antimicrob Chemother 2001;7(3):448-450.
19. Nagai K, Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. Single-and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 2001 Sep;48(3):365-374.
20. Serrano MC, Ramírez M, Morilla D, Valverde A, Chávez M, Espinel-Ingroff A, et al. A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp. J Antimicrob Chemother 2004 May;53(5):739-742.
21. Kiehlbauch JA, Hannett GE, Salfinger M, Archinal W, Monserrat C, Carlyn C. Use of the National Committee for Clinical Laboratory Standards guidelines for disk diffusion susceptibility testing in New York state laboratories. J Clin Microbiol 2000 Sep;38(9):3341-3348.
22. Masood H, Naqvi SB, Aslam N. Cost effective analysis of different brands of ceftriaxone available in Karachi, Pakistan. Pak J Pharmacol 2008;25:13-19.
23. CLSI. Performance standards for antimicrobial disk susceptibility tests; Approved standard, 2006, 16th edition. vol 28 (8) M31-A3, Wayne, Pennsylvania, USA., p.1-37.
24. Schwalbe R, Steele-Moore L. Goodwin.AC. Antimicrobial susceptibility testing protocols,2007; Taylor & Francis Group, pp.62.
25. Khushal R. Prevalence, characterization and development of resistance pattern in indigenous clinical isolates against cephalosporins. Ph.D Thesis. 2004. Department of Biological Sciences/ Quaid-i-Azam University, Islamabad, Pakistan. p. 1-10.
26. Lontie ML, Van Erdeweghe PE. Sensitivity to Ciprofloxacin of Escherichia coli Isolated from Urine According to Gender and Age. Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.).
27. Babay HA. Antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa from patients in a teaching hospital, Riyadh, Saudi Arabia, 2001-2005. Jpn J Infect Dis 2007 May;60(2-3):123-125.
28. Glupczynski Y, Delmée M, Goossens H, Struelens M; Belgian Multicenter ICU Study Group. Distribution and prevalence of antimicrobial resistance among gram-negative isolates in intensive care units (ICU) in Belgian hospitals between 1996 and 1999. Acta Clin Belg 2001 Sep-Oct;56(5):297-306.
29. Pong A, Thomson KS, Moland ES, Chartrand SA, Sanders CC. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother 1999 Nov;44(5):621-627.
30. Dajcs JJ, Thibodeaux BA, Marquart ME, Girgis DO, Traidej M, O’Callaghan RJ. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother 2004 Jun;48(6):1948-1952.
31. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit–a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004 Jul;3:14.
32. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999 Jul;106(7):1313-1318.
33. Mengo DM, Kariuki S, Muigai A, Revathi G. Trends in Salmonella enteric serovar Typhi in Nairobi, Kenya from 2004 to 2006. J Infect Dev Ctries 2010;4(6):393-396.
34. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004 May;82(5):346-353.
35. Krishnan P, Stalin M, Balasubramanian S. Changing trends in antimicrobial resistance of Salmonella enterica serovar typhi and salmonella enterica serovar paratyphi A in Chennai. Indian J Pathol Microbiol 2009 Oct-Dec;52(4):505-508.
36. Bhatia JK, Mathur AD, Arora MM. Re-emergence of Chloramphenicol Sensitivity in Enteric Fever. MJAFI 2007;63:212-214.
37. Threlfall JE, Ward LR. Decreased Susceptibility to Ciprofloxacin in Salmonella enterica serotype Typhi, United Kingdom. CDC. 2001; 7(3).
38. Gaind R, Paglietti B, Murgia M, Dawar R, Uzzau S, Cappuccinelli P, et al. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India. J Antimicrob Chemother 2006 Dec;58(6):1139-1144.
39. Chande C, Shrikhande S, Kapale S, Agrawal S, Fule RP. Change in antimicrobial resistance pattern of Salmonella Typhi in central India. Indian J Med Res 2002 Jun;115:248-250.
40. Rao PS, Rajashekar V, Varghese GK, Shivananda PG. Emergence of multidrug-resistant Salmonella typhi in rural southern India. Am J Trop Med Hyg 1993 Jan;48(1):108-111.
41. M.A. Campos, A. Arias, C. Rodriguez, A. Dorta, L. Betancor, D Loperz-Aguado, et al., Etiology and therapy of chronic suppurative otitis, J Chemother 1995; 7: 427_/431.
42. Hu XH, Xu XM, Mi ZH, Fan YF, Feng WY. [Relationship between drug resistance of Pseudomonas aeruginosa isolated from burn wounds and its mobile genetic elements]. Zhonghua Shao Shang Za Zhi 2009 Apr;25(2):103-105.
43. Fujimura T, Anan N, Sugimori G, Watanabe T, Jinushi Y, Yoshida I, et al. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Int J Antimicrob Agents 2009 Dec;34(6):523-528.
44. W.H. Sheng, Y.C. Chen, J.T. Wang, S.C. Chang, K.T. Luh, W.C. Hsieh, Emerging fluoroquinolone-resistance for common clinically important gram negative bacteria in Taiwan, Diagn Microbiol Infect Dis 2002; 43: 141_/147.
45. Schumacher H, Scheibel J, Moller JK. Cross-resistance patterns among clinical isolates of Klebsiella pneumoniae with decreased susceptibility to cefuroxime. J Antimicrob Chemother 2000 Aug;46(2):215-221.
46. Thomson CJ. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J Antimicrob Chemother 1999 Mar;43(Suppl A):31-40.
47. Fuursted K, Schumacher H. Significance of low-level resistance to ciprofloxacin in Klebsiella pneumoniae and the effect of increased dosage of ciprofloxacin in vivo using the rat granuloma pouch model. J Antimicrob Chemother 2002 Sep;50(3):421-424.
48. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994 Aug;331(6):377-382.